Table 3 QLQ-ANL27 questionnaire: patient-, tumor- and therapy-related factors.
From: Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer
Factors | No. | Bowel function non-stoma | Sexual function male | Sexual function female | Pain | Micturition frequency | Leg oedema | Toilet proximity | Cleanliness | Planning activities |
|---|---|---|---|---|---|---|---|---|---|---|
Tumor stage | ||||||||||
T1/2 | 33 | 78.3 (16) | 63.0 (13) | 75.2 (15) | 19.7 (17) | 20.2 (22) | 21.2 (17) | 22.2 (26) | 27.3 (27) | 18.2 (25) |
T3/4 | 19 | 69.0 (19) | 66.7 (17) | 70.8 (11) | 31.0 (17)* | 31.6 (32) | 36.8 (25)* | 31.6 (32) | 26.3 (31) | 28.1 (20) |
Lymph node status | ||||||||||
N0 | 29 | 75.3 (18) | 66.7 (14) | 71.0 (17) | 23.3 (18) | 18.3 (24) | 25.8 (24) | 24.7 (30) | 30.1 (26) | 23.7 (26) |
N+ | 21 | 75.7 (16) | 61.9 (14) | 78.2 (6) | 24.6 (18) | 27.0 (33) | 27.0 (33) | 27.0 (25) | 22.2 (30) | 19.0 (20) |
UICC | ||||||||||
I/II | 29 | 75.1 (19) | 66.7 (14) | 70.8 (17) | 22.6 (19) | 19.5 (24) | 24.1 (23) | 23.0 (27) | 31.0 (26) | 21.8 (26) |
III/IV | 23 | 75.9 (16) | 61.9 (14) | 77.4 (7) | 25.4 (17) | 24.6 (32) | 29.0 (25) | 29.9 (25) | 21.7 (29) | 21.7 (22) |
Tumor relapse | ||||||||||
Without relapse | 43 | 76.7 (18) | 66.7 (13) | 75.1 (15) | 20.3 (18) | 18.6 (26) | 21.7 (23) | 19.4 (25) | 22.5 (27) | 17.8 (23) |
With relapse | 9 | 62.5 (5) | 58.3 (18) | 65.6 (7) | 40.7 (7)* | 37.0 (35) | 48.2 (18)* | 55.6 (24)* | 48.2 (24)* | 40.7 (15)* |
RT technique | ||||||||||
IMRT | 14 | 80.6 (11) | 58.3 (8) | 79.8 (6) | 23.0 (17) | 21.4 (31) | 28.6 (26) | 19.0 (25) | 28.6 (32) | 16.7 (17) |
3D | 14 | 57.3 (20)* | 61.7 (20) | 55.6 (16)* | 38.9 (19) | 35.7 (29) | 42.9 (25) | 47.6 (32)* | 40.5 (27) | 42.9 (24)* |
Dose | ||||||||||
< 55.8 | 27 | 74.9 (16) | 60.4 (14) | 68.4 (17) | 24.7 (19) | 22.2 (32) | 27.2 (25) | 33.3 (31) | 28.4 (22) | 23.5 (27) |
> 55.8 | 21 | 77.8 (15) | 70.8 (16) | 78.5 (6)* | 23.3 (14) | 20.6 (22) | 28.6 (24) | 17.5 (23)* | 25.4 (31) | 22.2 (19) |
Gender | ||||||||||
Female | 38 | 75.8 (17) | – | – | 23.4 (18) | 18.4 (25) | 27.2 (24) | 27.2 (30) | 25.4 (29) | 20.2 (21) |
Male | 14 | 74.5 (20) | 25.0 (19) | 31.0 (33) | 23.8 (24) | 21.4 (25) | 31.0 (24) | 26.2 (30) | ||
Age at QoL assessment | ||||||||||
< 70 years | 35 | 79.7 (12) | 67.7 (17) | 74.6 (13) | 19.4 (17) | 19.1 (26) | 24.8 (25) | 23.8 (29) | 22.9 (23) | 19.1 (22) |
> 70 years | 17 | 67.7 (22)* | 60.7 (9) | 71.7 (18) | 33.0 (18)* | 27.5 (32) | 29.4 (23) | 29.4 (29) | 35.3 (34) | 27.5 (27) |
Follow-up period | ||||||||||
< 71 months | 27 | 82.6 (11) | 66.7 (14) | 80.4 (8) | 16.5 (15) | 18.5 (27) | 17.3 (19) | 21.0 (26) | 18.5 (23) | 13.6 (17) |
> 71 months | 25 | 67.9 (20)* | 61.1 (16) | 67.8 (16)* | 31.8 (17)* | 25.3 (29) | 36.0 (25)* | 30.7 (30) | 36.0 (30)* | 30.7 (27)* |
